Revisit Every OncLive On Air Episode From December 2025

As the year winds down, here’s a look back at the episodes of OncLive On Air^® that debuted in December 2025. If you missed any, catch up now, and explore the full lineup on our podcast page to stay current on the latest conversations shaping oncology care.

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

In this episode, we spoke with Sarah Rutherford, MD, of Weill Cornell Medicine in New York, New York, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing in lymphoma. Dr Rutherford discussed how ctDNA assays may help guide treatment decisions, ongoing clinical trials aimed at defining optimal use of these tools, and the potential for personalized ctDNA testing to support disease surveillance and early intervention. She also addressed current barriers to broad clinical implementation and outlined how integration with next-generation sequencing may further refine risk stratification and treatment personalization in lymphoma care.

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

In this episode, Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD, all from John Theurer Cancer Center in Hackensack, New Jersey, discussed the use of pressurized intraperitoneal aerosolized chemotherapy in patients with peritoneal metastases or primary peritoneal cancers. They explained that this laparoscopic approach addresses many limitations of traditional systemic treatments and allows for uniform drug distribution and deeper tissue penetration that deliver enhanced efficacy with lower systemic drug concentrations.

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

In this episode, Catherine Shu, MD, of the Columbia University Herbert Irving Comprehensive Cancer Center in New York, discussed treatment with tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Dr Shu reviewed updated data from the phase 2 VISION trial (NCT02864992) of tepotinib in this population, the efficacy of this agent in treatment-naive patients, and safety considerations associated with this therapy.

Hepatic Artery Infusion Refines Liver-Directed Care for GI Cancers: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

In this episode, Drs Tiesi, Scholer, Golas, and Pletcher discussed the role of hepatic artery infusion (HAI) in the treatment of patients with colon cancer and primary liver malignancies. The panel emphasized that HAI is a well-established regional therapy for patients with primary or metastatic liver tumors, particularly unresectable colorectal liver metastases and intrahepatic cholangiocarcinoma. They explained that HAI exploits the liver’s dual blood supply, as these tumors predominantly receive perfusion from the hepatic artery rather than the portal vein. By delivering chemotherapy directly into the hepatic arterial circulation via the gastroduodenal artery, HAI enables high intratumoral drug concentrations and limits systemic exposure, thereby enhancing antitumor efficacy and reducing extrahepatic toxicity.

How Compelling Communication Makes Early Cancer Detection Part of Everyday Life: With D. Ross Camidge, MD, PhD; and Keith Singer

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Keith Singer of Catch It In Time. Camidge and Singer discussed how Singer's prolific career in broadcasting and cable television evolved into a passion for promoting cancer awareness.

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, was joined by Panagiotis (Panos) A. Konstantinopoulos, MD, PhD, also of Dana-Farber Cancer Institute. The experts differentiated between subtypes of endometrial cancer and highlighted recent treatment developments for this disease.

ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis; and Karine Tawagi, MD, of the University of Illinois in Chicago, spotlighted updates in chronic lymphocytic leukemia (CLL) research that were presented at the 2025 ASH Annual Meeting. The experts discussed the prevalence of CLL in asymptomatic, elderly patients presenting with lymphocytosis, how to establish a definitive diagnosis of this disease, and disease characteristics that warrant treatment initiation.

Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH

In this episode, Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH, both of City of Hope, explained unique characteristics of IB6 as a NSCLC biomarker, the prevalence of IB6 expression in lung cancer cases, and the rationale for investigating sigvotatug vedotin (formerly SGN-B6A) compared with docetaxel in patients with previously treated NSCLC in the phase 3 Be6A Lung-01 trial (NCT06012435).

Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD

In this episode, Pooja M. Phull, MD, of Hackensack University Medical Center in New Jersey, highlighted findings from an investigation of the fecal microbiome of patients with newly diagnosed myeloma, which showed that depletion of short-chain, fatty acid–producing organisms following transplant was associated with inferior progression-free survival outcomes.

ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD

In this episode, Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center in Houston, highlighted the role of ctDNA testing in early-stage breast cancer management, how ctDNA testing has evolved to become a potential clinical decision-making aid, data that may support the predictive value of ctDNA negativity after neoadjuvant therapy, and the importance of discussing ctDNA testing with patients.

How Biostastistics Expertise Led to a Career of Propelling Ethical Clinical Trial Design: D. Ross Camidge, MD, PhD; and Tom Fleming, PhD

In this episode of How This Is Building Me, Dr Camidge was joined by Tom Fleming, PhD, of the University of Washington School of Public Health in Seattle, to highlight how Dr Fleming's curiosity about biostatistics evolved into a career advocating for scientifically rigorous and unbiased clinical trial design.

MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD

In this episode, Kathryn S. Nevel, MD, of Indiana University Health; and Michael Veronesi, MD, PhD, of the University of Wisconsin School of Medicine and Public Health in Madison, hosted an OncLive Ask the Expert presentation about evolving imaging strategies for patients with glioma.

Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD

In this episode, Julia Rotow, MD, of Dana-Farber Cancer Institute; and Gavitt Woodard, MD, of the Yale School of Medicine in New Haven, Connecticut, discussed practice-informing updates to the perioperative non–small cell lung cancer treatment paradigm.

FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD

In this episode, Christof Vulsteke, MD, PhD, of the Integrated Cancer Center Ghent in Belgium, discussed the significance of the FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for the treatment of patients with cisplatin-ineligible muscle-invasive bladder cancer.

CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

In this episode, Joanna M. Rhodes, MD, MSCE, of Rutgers Cancer Institute of New Jersey in New Brunswick; and Krish Patel, MD, of the Sarah Cannon Research Institute in Nashville, Tennessee, explained ways that the CLL treatment paradigm is evolving to reflect advances in targeted therapy.